news
AI holds promise to accelerate drug repurposing for COVID-19
According to a new report, artificial intelligence (AI) is vital for the rapid identification of drugs that can be repurposed to combat COVID-19.
List view / Grid view
BenevolentAI
article
Beyond the phenotype: using AI to better understand disease
Claus Bendtsen at AstraZeneca reveals how AI can be used to improve our understanding of disease, to help identify the causes of conditions and aid in drug discovery.
news
BenevolentAI to partner with medical research charity MRC technology
BenevolentAI, a British artificial intelligence company, has partnered with MRC Technology (MRCT), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies.
article
Turning rare diseases into efficient targets with AI
BenevolentBio's CMO, Dr Patrick Keohane, says the industry is on the cusp of an artificial intelligence (AI) revolution...
news
BenevolentAI becomes first AI company to appoint a Chief Medical Officer
BenevolentAI is the first AI company to have a CMO on its staff.
article
How artificial intelligence is the future of pharma
5 December 2016 | By Professor Jackie Hunter, BenevolentBio
Artificial Intelligence and machine learning present the industry with a real opportunity to do R&D differently, writes BenevolentBio's Jackie Hunter...
news
UK Artificial Intelligence firm signs license with Janssen for drug candidate
9 November 2016 | By Niamh Louise Marriott, Digital Content Producer
BenevolentAI, a British artificial intelligence company has signed an exclusive license for a series of novel clinical stage drug candidates with Janssen...
